STOCK TITAN
  1. Home
  2. Sec-filings
  3. SUPN
  4. [Form 4] SUPERNUS PHARMACEUTICALS, INC. Insider Trading Activity

Supernus (NASDAQ: SUPN) SVP sells 8,877 shares after exercising 7,500 PSUs

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Supernus Pharmaceuticals SVP, Commercial Operations William Todd Horich reported a series of stock transactions involving performance-based awards and subsequent sales. On March 6, 2026, he exercised performance share units to acquire 7,500 shares of common stock at $0.00 per share. In connection with this vesting, the company withheld 3,455 shares at about $54.73 per share to cover tax obligations, as disclosed in the footnotes.

He then executed open-market sales of common stock, selling 4,438 shares at $54.00 on March 9 and 4,439 shares at $55.00 on March 10. After these transactions, his directly held common stock position reported in this filing was reduced to zero shares. The filing shows no remaining derivative holdings, indicating all reported performance share units tied to these transactions were fully settled.

Positive

  • None.

Negative

  • None.
Insider Horich William Todd
Role SVP, Commercial Operations
Sold 8,877 shs ($484K)
Type Security Shares Price Value
Sale Common Stock 4,439 $55.00 $244K
Sale Common Stock 4,438 $54.00 $240K
Exercise Performance Share Unit 2,625 $0.00 --
Exercise Performance Share Unit 3,750 $0.00 --
Exercise Performance Share Unit 1,125 $0.00 --
Exercise Common Stock 2,625 $0.00 --
Tax Withholding Common Stock 1,216 $54.73 $67K
Exercise Common Stock 3,750 $0.00 --
Tax Withholding Common Stock 1,718 $54.73 $94K
Exercise Common Stock 1,125 $0.00 --
Tax Withholding Common Stock 521 $54.73 $29K
Holdings After Transaction: Common Stock — 0 shares (Direct); Performance Share Unit — 0 shares (Direct)
Footnotes (1)
  1. Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Horich William Todd
(Last) (First) (Middle)
C/O SUPERNUS PHARMACEUTICALS, INC.,
9715 KEY WEST AVENUE
(Street)
ROCKVILLE MD 20850
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
SUPERNUS PHARMACEUTICALS, INC. [ SUPN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP, Commercial Operations
3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/06/2026 M 2,625 A $0 7,457 D
Common Stock 03/06/2026 F(1) 1,216 D $54.73 6,241 D
Common Stock 03/06/2026 M 3,750 A $0 9,991 D
Common Stock 03/06/2026 F(1) 1,718 D $54.73 8,273 D
Common Stock 03/06/2026 M 1,125 A $0 9,398 D
Common Stock 03/06/2026 F(1) 521 D $54.73 8,877 D
Common Stock 03/09/2026 S 4,438 D $54 4,439 D
Common Stock 03/10/2026 S 4,439 D $55 0 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Performance Share Unit $0 03/06/2026 M 2,625 (2) (2) Common Stock 2,625 $0 0 D
Performance Share Unit $0 03/06/2026 M 3,750 (2) (2) Common Stock 3,750 $0 0 D
Performance Share Unit $0 03/06/2026 M 1,125 (2) (2) Common Stock 1,125 $0 0 D
Explanation of Responses:
1. Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.
2. On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024.
Remarks:
/s/ Timothy C. Dec, as attorney-in-fact 03/10/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Supernus (SUPN) executive William Todd Horich report in this Form 4?

He reported exercising performance share units into 7,500 shares of Supernus common stock, with 3,455 shares withheld for taxes, and then selling 8,877 shares in open-market transactions, leaving no directly held shares reported in this filing.

How many Supernus (SUPN) shares did the SVP sell and at what prices?

William Todd Horich sold a total of 8,877 Supernus common shares in the open market, including 4,438 shares at $54.00 per share and 4,439 shares at $55.00 per share, across trades dated March 9 and March 10, 2026.

What is the role of tax withholding in this Supernus (SUPN) Form 4?

The company withheld 3,455 Supernus shares at approximately $54.73 per share to satisfy tax withholding requirements related to the vesting of performance share units, meaning these F-code dispositions were for tax obligations rather than discretionary open-market stock sales.

Did the Supernus (SUPN) SVP retain any common stock after these transactions?

According to the reported holdings after the final sale, William Todd Horich’s directly held Supernus common stock position was reduced to zero shares, indicating no remaining directly owned common shares are shown in this particular Form 4 filing.

What type of awards were exercised in the Supernus (SUPN) Form 4?

The filing shows performance share units that were awarded on February 22, 2024 and vested upon meeting individual performance objectives. These performance share units were exercised into 7,500 shares of Supernus common stock at a conversion price of $0.00 per share.

Does this Supernus (SUPN) Form 4 show any remaining derivative securities?

The derivative summary section is empty in this Form 4, and performance share unit entries show zero remaining following the exercises, indicating all derivative securities tied to these reported awards were fully converted and no additional derivative position is listed.